OFFICE OF PHARMACY AFFAIRS 340B PROGRAM REGISTRATION FORM FOR SEXUALLY TRANSMITTED DISEASE/TUBERCULOSIS CLINICS

Acknowledgement of Covered Entity Participation in Outpatient Discount Drug Pricing under Section 340B of the Public Health Service Act.

I. Covered Entity Information:		
Covered Entity Name:		
Covered Entity Sub-Division Name (if applicable):		
Employer Identification Number:		
Street Address (PO Boxes are not allowed):		
City:	State:	ZIP:
Billing Address (if different):		
City:	State:	ZIP:
Shipping Address (if different; PO Boxes are not allowed)		
City:	State:	ZIP:
Are you attempting to reinstate under a previous 340B ID num Yes 340B ID Number: No		_
Federal Grant Number:		
Notice of Funding Opportunity (NOFO) Number:		
Nature of Support:		
Direct Funding (dollars received from CDC or an int	ermediate organ	ization)
"In-kind" products or services purchased with Section 318/317 funds		
 Please describe the "in-kind" support: 		
□ None Note: In-kind contributions may be in the form of reapproperty, and goods and services directly benefiting		•
Time period the 318/317 funding or in-kind support was	received: From_	to
II. Medicaid Billing Information: You must answer the follow	ving question reg	narding Medicaid billing.

If the answer is yes, please provide the state(s) and associated billing number(s) listed on the claims to bill Medicaid fee-for-service for particular states that you plan to bill for 340B drugs in the space(s) below (this could include numbers for the state your hospital is located in and any out-of-state Medicaid agencies your hospital plans to bill for 340B drugs). All numbers you plan to use to bill Medicaid fee-for-service should be provided and may include the billing provider's national provider identifier (NPI) only, state assigned Medicaid number only, or both the NPI and state assigned Medicaid number. Do not list a state for which the covered entity will not bill Medicaid fee-for-service for drugs purchased at 340B prices.

Yes □ No □

At this site, will the covered entity bill Medicaid fee-for-service for drugs purchased at 340B prices?

HRSA exports the Medicaid billing information listed in this site's 340B OPAIS record to generate the quarterly Medicaid exclusion file (MEF). HRSA requires the information on the MEF be accurate and complete for every registered site in the 340B OPAIS, and that

covered entities follow any additional state Medicaid requirements in order to prevent duplicate discounts.

While this site may request a change to its 340B OPAIS record at any time, the Medicaid fee-for service billing practice at this site, must match the quarterly MEF.

State	State Assigned	NPI
	Medicaid Number	

All covered entities should notify OPA prior to any change in Medicaid billing status. For more information, please visit the HRSA website.

Covered Entity Primary Contact (Must be someone employed by	ct Name by the Covered Entity):		
Title:			
Phone:		Fax:	
Email Address:			
Vice President, Chief Executive Forms that are signed by an inprocessed. If you are in doubt Prime Vendor Program at 1-88 your registration.	e someone who can bind the organizat e Officer, Chief Operating Officer, Chief dividual that OPA determines is not an regarding the acceptability of a signatur 8-340-2787 or via email at ApexusAnsy	Financial Officer, or Executive Dire acceptable representative will not be re, please contact please contact the wers@340bpvp.com prior to submis	ctor. e e 340B
Phone:		Fax:	
Email Address:			

IV. Signed Agreement:

The undersigned represents and confirms that he/she is fully authorized to legally bind the covered entity into a contract and certifies that the contents of any statement made or reflected in this document are truthful and accurate. The undersigned further acknowledges the 340B covered entity's responsibility to abide by the following:

As an Authorized Official, I certify on behalf of the covered entity that:

- (1) all information listed on the 340B Program database for the covered entity will be complete, accurate, and correct;
- (2) the covered entity will meet all 340B Program eligibility requirements;
- (3) the covered entity will comply with all requirements of Section 340B of the Public Health Service Act and any accompanying regulations including, but not limited to, the prohibition against duplicate discounts and diversion (section 340B(a)(5)(A) and (B) of the Public Health Service Act;
- (4) the covered entity will maintain auditable records pertaining to compliance with the requirements described in paragraph (3) above, pursuant to section 340B(a)(5)(C) of the Public Health Service Act;
- (5) if the covered entity uses contract pharmacy services, that the contract pharmacy arrangement will be performed in accordance with OPA requirements and guidelines;
- (6) the covered entity acknowledges its responsibility to contact OPA as soon as possible if there is any change in 340B eligibility and/or breach by the covered entity of any of the foregoing; and

Dept. of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau OMB No. 0915-0327;

(7) the covered entity acknowledges that if there is a breach of the requirements described in paragraph (3) that the covered entity may be liable to the manufacturer of the covered outpatient drug that is the subject of the violation, and, depending upon the circumstances, may be subject to removal from the list of eligible 340B entities.

In addition, I have read all applicable registration instructions and I am aware that my registration will not be reviewed if the required supporting documents are not submitted today.

Please provide any additional information or clarification that may be helpful in reviewing this registration for 340B progra Higibility:			
Signature of Authorizing Official:	Date:		

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0915-0327. Public reporting burden for this collection of information is estimated to average 1 hours per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 14N-39, Rockville, Maryland, 20857.